Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—ertapenem, metronidazole, and cefdinir—each with distinct mechanisms of action. Ertapenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa; it disrupts DNA synthesis in susceptible organisms. Cefdinir is an oral third-generation cephalosporin that also inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins but has a different spectrum of activity compared to ertapenem. This combination would provide broad-spectrum coverage against aerobic Gram-positive and Gram-negative bacteria (ertapenem, cefdinir) as well as anaerobes (metronidazole). Such combinations are sometimes used or considered for complicated intra-abdominal infections or other polymicrobial infections where broad coverage is needed[1][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ertapenem + metronidazole + cefdinir.